ReviewInnere Medizin (Heidelberg, Germany)2026
[Polypharmacy and nephrotoxicity].
Review in Innere Medizin (Heidelberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPolypharmacy is common among older adults. Renal effects can range from mild functional increases in creatinine to structural tubular injury.
objectiveThe aim of the study was to systematically describe nephrotoxicity in the context of polypharmacy, identify typical pharmacokinetic and pharmacodynamic constellations, and introduce the concept of "nephrotoxic burden" as a potential tool for quantitative risk assessment. MATERIALS AND
methodsA selective review of the literature on drug-induced nephrotoxicity and drug-drug interactions was performed.
resultsPharmacokinetic interactions leading to renal adverse drug reactions typically occur when dose-dependent nephrotoxic agents such as calcineurin inhibitors reach toxic concentrations through cytochrome P450 3A4 (CYP3A4) inhibition (e.g., by macrolides, azoles, or ritonavir). Pharmacodynamic interactions associated with renal effects are observed, for example, with the combination of nonsteroidal anti-inflammatory drugs (NSAIDs), angiotensin-converting enzyme (ACE) inhibitors, and diuretics, or with combinations of vancomycin and aminoglycosides or piperacillin. The concept of nephrotoxic burden addresses the risk of acute kidney injury (AKI) from concurrent use of multiple nephrotoxic drugs but currently lacks adequate differentiation between underlying mechanisms.
conclusionsIn patients receiving calcineurin inhibitors, any additional prescriptions should be carefully reviewed for potential interactions and accompanied by dose adjustment and close therapeutic drug monitoring where appropriate. The concurrent use of several agents with structural tubular toxicity generally increases risk, whereas functional mechanisms, such as those seen with combined ACE inhibitor and sodium-glucose cotransporter 2 inhibitor (SGLT2) inhibitor therapy, are usually well tolerated. The concept of nephrotoxic burden shows promise but requires further refinement and prospective validation before it can serve as a practical tool for risk stratification in polypharmacy.
Indexed as
Identifiers
41535444What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.